AstraZeneca has published a new study that demonstrates that Symbicort Inhalation Aerosol 320/9 μg twice daily has a safety profile similar to Budesonide pressurized metered-dose inhaler (pMDI) 320 μg twice daily for asthma. In a ...
Tags: asthma, drug relationship, use of Symbicort
Astellas Pharma and AstraZeneca have announced the approval of the dry-power inhaler Symbicort Turbuhaler for the additional indication of chronic obstructive pulmonary disease(COPD). Symbicort Turbuhaler is a combination product ...
Tags: Astellas Pharma, AstraZeneca, dry-power inhaler Symbicort Turbuhaler
Watson Laboratories,a subsidiary of Watson Pharmaceuticals,has won FDA approval for its abbreviated new drug application(ANDA)for Budesonide inhalation suspension 0.25mg/2mL and 0.5mg/2mL unit-dose ampoules. Budesonide Inhalation ...
Ten biopharmaceutical companies, Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech and Sanofi have established a non-profit organization ...
Tags: biopharmaceutical companies, non-profit organization, new medicines
Computer Weekly has announced the third UKtech50, our annual definitive list of the real movers and shakers in UK IT - the CIOs, industry executives, public servants and business leaders driving the role of technology in the UK economy. ...
Tags: UK IT, UKtech50, ARM, GCHQ, Government Digital Service, Salesforce.com
UK targeted attacks have gone from four a year to 500 a day in just two years, according to Misha Glenny, security author and journalist. "But it is not just big corporations that are being targeted, attackers are going after everyone in ...
Tags: RSA Europe, Supply Chain, Misha Glenny, London conference
AstraZeneca, a biopharmaceutical company, has completed the purchase of a US-based biotechnology company, Ardea Biosciences. Upon completion of the merger, approved by Ardea's stockholders, each outstanding share of Ardea common stock has ...
Tags: purchase, AstraZeneca, Ardea Biosciences, biopharmaceutical
AstraZeneca and Ardea Biosciences have entered into a definitive merger agreement, under which AstraZeneca will acquire Ardea for $1.26bn including a product lesinurad in Phase III development for gout. As per the agreement, AstraZeneca ...
Tags: AstraZeneca, Ardea, merger agreement, gout